These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. Guo RQ; Guo XX; Li YM; Bie ZX; Li B; Li XG Int J Clin Oncol; 2021 Mar; 26(3):461-484. PubMed ID: 33387088 [TBL] [Abstract][Full Text] [Related]
28. Photosensitizers in prostate cancer therapy. Gheewala T; Skwor T; Munirathinam G Oncotarget; 2017 May; 8(18):30524-30538. PubMed ID: 28430624 [TBL] [Abstract][Full Text] [Related]
29. Re: TOOKAD ® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. Taneja SS J Urol; 2014 Apr; 191(4):983-4. PubMed ID: 24703118 [No Abstract] [Full Text] [Related]
30. Re: TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. Cadeddu JA J Urol; 2014 May; 191(5):1290. PubMed ID: 24745491 [No Abstract] [Full Text] [Related]
31. Prompt assessment of WST11-VTP outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate. Fleshker S; Preise D; Kalchenko V; Scherz A; Salomon Y Photochem Photobiol; 2008; 84(5):1231-7. PubMed ID: 18399928 [TBL] [Abstract][Full Text] [Related]
32. Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer. Flegar L; Baunacke M; Buerk BT; Proschmann R; Zacharis A; Propping S; Huber J; Thomas C; Borkowetz A Urol Int; 2022; 106(9):903-908. PubMed ID: 34814157 [TBL] [Abstract][Full Text] [Related]
33. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11]. Lebdai S; Martin F; Bigot P; Azzouzi AR Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031 [TBL] [Abstract][Full Text] [Related]
34. A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. Bates AS; Ayers J; Kostakopoulos N; Lumsden T; Schoots IG; Willemse PM; Yuan Y; van den Bergh RCN; Grummet JP; van der Poel HG; Rouvière O; Moris L; Cumberbatch MG; Lardas M; Liew M; Van den Broeck T; Gandaglia G; Fossati N; Briers E; De Santis M; Fanti S; Gillessen S; Oprea-Lager DE; Ploussard G; Henry AM; Tilki D; van der Kwast TH; Wiegel T; N'Dow J; Mason MD; Cornford P; Mottet N; Lam TBL Eur Urol Oncol; 2021 Jun; 4(3):405-423. PubMed ID: 33423943 [TBL] [Abstract][Full Text] [Related]
35. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. Madar-Balakirski N; Tempel-Brami C; Kalchenko V; Brenner O; Varon D; Scherz A; Salomon Y PLoS One; 2010 Apr; 5(4):e10282. PubMed ID: 20421983 [TBL] [Abstract][Full Text] [Related]
36. Current evidence for focal laser ablation and vascular-targeted photodynamic therapy for localized prostate cancer: review of literature published in the last 2 years. Candela L; Kasraeian A; Barret E Curr Opin Urol; 2022 Mar; 32(2):192-198. PubMed ID: 35013079 [TBL] [Abstract][Full Text] [Related]
37. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Davidson SR; Weersink RA; Haider MA; Gertner MR; Bogaards A; Giewercer D; Scherz A; Sherar MD; Elhilali M; Chin JL; Trachtenberg J; Wilson BC Phys Med Biol; 2009 Apr; 54(8):2293-313. PubMed ID: 19305043 [TBL] [Abstract][Full Text] [Related]
38. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Gross N; Ranjbar M; Evers C; Hua J; Martin G; Schulze B; Michaelis U; Hansen LL; Agostini HT Mol Vis; 2013; 19():54-61. PubMed ID: 23335851 [TBL] [Abstract][Full Text] [Related]
39. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model. Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311 [TBL] [Abstract][Full Text] [Related]
40. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. Eymerit-Morin C; Zidane M; Lebdai S; Triau S; Azzouzi AR; Rousselet MC Virchows Arch; 2013 Oct; 463(4):547-52. PubMed ID: 23948957 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]